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Abstract
Background: Treatment limitation decisions (TLDs) on the ICU can be challenging, especially in patients with a malignancy.
Up-to-date literature regarding TLDs in critically ill patients with a malignancy admitted to the ICU is scarce. The aim was to
compare the incidence of written TLDs between patients with an active malignancy, patients with a malignancy in their medical
history (complete remission, CR) and patients without a malignancy admitted unplanned to the ICU.Methods:We conducted a
retrospective cohort study in a large university hospital in the Netherlands. We identified all unplanned admissions to the ICU in
2017 and categorized the patients in 3 groups: patients with an active malignancy (study population), with CR and without a
malignancy. A TLD was defined as a written instruction not to perform life-saving treatments, such as CPR in case of cardiac
arrest. A multivariate binary logistic regression analysis was used to identify whether having a malignancy was associated with
TLDs. Results: Of the 1046 unplanned admissions, 125 patients (12%) had an active malignancy and 76 (7.3%) patients had CR.
The incidence of written TLDs in these subgroups were 37 (29.6%) and 20 (26.3%). Age (OR 1.03; 95% CI 1.01 -1.04), SOFA score
at ICU admission (OR 1.11; 95% CI 1.05 -1.18) and having an active malignancy (OR 1.75; 95% CI 1.04-2.96) compared to no
malignancy were independently associated with written TLDs. SOFA scores on the day of the TLD were not significantly different
in patients with and without a malignancy. Conclusions: This study shows that the presence of an underlying malignancy is
independently associated with written TLDs during ICU stay. Patients with CR were not at risk of more written TLDs. Whether
this higher incidence of TLDs in patients with a malignancy is justified, is at least questionable and should be evaluated in future
research.
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Introduction
Invasive life-saving treatments, provided at an intensive care
unit (ICU), have been increasingly offered to patients with
potentially lifespan limiting conditions, such as a malig-
nancy.1-4 Even an increase in such treatments in the final stages
of life of these patients has been reported.3 These therapies
should not automatically be considered disproportional; how-
ever, the treatment intensity should remain proportional to the
expected outcome.1 In 2 large multicenter studies, perceptions of
inappropriate ICU care were frequently reported by clinicians.1,5
Approximately 30% of patients requiring cardiopulmonary
resuscitation (CPR) after an in-hospital cardiac arrest (IHCA)
survived the hospital admission,6 the survival of patients with
return of spontaneous circulation admitted to the ICU is up to
50%.7 In contrast, hospital survival of patients with a malig-
nancy requiring CPR after IHCA was significantly lower (5-
10%).8,9 Therefore, CPR can in certain circumstances be seen
as a traumatic, undignified and inappropriate medical interven-
tion,10,11 often with prolonged hospitalization and invasive
treatment as result.12,13 A decision to withhold invasive life-
saving treatments in case of a medical emergency, such as CPR
during a circulatory arrest, is called a treatment limitation deci-
sion (TLD) and is part of routine hospital practice.9 When
properly executed, a written TLD is a useful method to ensure
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that patient’s preferences regarding CPR or other invasive life-
saving treatments are honored.14-16
However, ICU patients often lack decision-making capac-
ity17,18 and advanced directives are often lacking or unclear.19-21
Cheveaux et al. showed that “having a malignancy” is associ-
ated with more do-not-resuscitate decisions at the ward, of
which more than half were made by the medical team.22 TLDs
on the ICU can be challenging, especially in patients with a
malignancy. Up-to-date literature regarding treatment limita-
tion decisions in critically ill patients with a malignancy admit-
ted unplanned to the ICU is scarce, despite rapid evolution of
diagnostics and cancer treatments. The number of patients with
a malignancy admitted unplanned to the ICU has been increas-
ing, and mortality rates in these patients are higher than in
unplanned ICU patients without a malignancy.4,23 A higher
incidence of written TLDs in critically ill patients with a malig-
nancy than in patients without a malignancy may be justified,
especially in patients with a poor short-term prognosis. In addi-
tion, TLDs may be justified when used for minimizing inap-
propriate invasive life-saving treatments in case of
deterioration in this vulnerable patient population. On the other
hand, in case of similar severity of illness between patients with
and without a malignancy, the presence of an underlying malig-
nancy should not automatically result in TLDs.
The primary objective of this study was to compare the inci-
dence of written TLDs between patients with an active malig-
nancy, patients with a malignancy in their medical history and
patients without a malignancy admitted unplanned to the ICU.
The secondary objective was to identify factors independently
associated with written TLDs in patients with a malignancy.
Methods
We conducted a retrospective cohort study in a large university
hospital ICU in theNetherlands (Rotterdam).Byusing our hospital
electronic database, we identified all unplanned admissions to the
ICU in the year 2017. Our ICU is amixed ICU in a tertiary referral
university hospital. We categorized the patients in 3 groups:
patients with an active malignancy (study population), patients
with a malignancy in their medical history (complete remission,
CR)andpatientswithout amalignancy.The studywasapprovedby
the ethical committee of our institute (MEC-2018-1172).
A metastatic solid tumor was defined as the presence of
cancer cells present in distant organs or distant lymph nodes,
determined by using the medical reports of hematologists and
oncologists. Patients with treatment for a malignancy in their
medical history and no signs of recurrence were defined as com-
plete remission (CR). We defined CR as no detectable malig-
nancy based on the information available in the electronic
database, medical reports and letters. We divided complete
remission in CR < 1 year and CR > 1 year, in order to examine
the influence of very recent CR compared to longer existent CR
in written TLDs. Late deleterious effects of cancer therapies can
occur even decades after completion of the cancer treatment,24-28
we therefore did not exclude patients with a malignancy, even
patients with a malignancy in their distant past.
Patients with a diagnosis of a non-melanoma skin malig-
nancy (squamous-cell skin cancer or basal-cell carcinoma)
were excluded because of the relatively favorable prognosis
of these tumors, usually without life threatening complications.
Similarly, we also excluded patients with a premalignant con-
dition, such as colon polyps.
A treatment limitation decision was defined as a written
instruction not to perform cardiopulmonary resuscitation in
case of a cardiac arrest, or a written instruction not to perform
other life-saving treatments, such as tracheal intubation and
mechanical ventilation in case of respiratory insufficiency or
renal replacement therapy in case of kidney insufficiency. An
actual withholding or withdrawal of ICU treatment during the
ICU admission was not mandatory to meet the definition, only
the written instruction. New written TLDs or an extension of an
existent of a written TLD during ICU admission were col-
lected. Furthermore, the reasons for the TLDs were collected.
ICU and patient characteristics were collected. The comor-
bidity of the patients was measured by using the Charlson
Comorbidity Index (CCI).29 The Eastern Cooperative Oncology
Group (ECOG) Performance Status was used to assess perfor-
mance status in the month to 14 days prior to the ICU admis-
sion.30 To evaluate the extent of the acute critical illness of the
patients at ICU admission, the Sequential Organ Failure Assess-
ment (SOFA) score was used.31 Unplanned ICU admissions
were defined as medical admissions and postoperative admission
after emergency surgery. Readmissions were defined as a new
ICU admission within 30 day after discharge from the ICU.
The primary objective of this study was to compare the
incidence of written TLDs between patients with an active
malignancy, patients with CR and patients without a malig-
nancy admitted unplanned to the ICU. The secondary objective
was to identify factors independently associated with written
TLDs in patients with an active malignancy.
Statistical Analysis
Descriptive statisticswere used to describe baseline and ICUchar-
acteristics. Categorical variables are reported as numbers with
percentage. Continuous variables are reported as mean and stan-
darddeviation for normallydistributeddata, or, in caseof a skewed
distribution, median with 25th–75th interquartile range (IQR).
Primary outcome. In order to analyze differences in baseline
characteristics between patients with and without a malignancy
with a new written TLD, we used Pearson’s Chi-square tests or
the Fisher’s exact tests for categorical variables and Indepen-
dent Samples T-Tests (normal distribution) or the Mann-
Whitney U tests (skewed distributions) for continuous vari-
ables. A statistical test with a 2 tailed p value  0.05 was
considered as significant.
To explore whether having a malignancy was independently
associated with a written TLD, a univariate logistic regression
analysis was used including the following variables: malig-
nancy status (i.e. no malignancy, active malignancy, CR and
both active and CR), age, gender and SOFA score at admission.
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Subsequently, variables with a p-value < 0.2 in the univariate
analysis were analyzed in a multivariate binary logistic regres-
sion analysis. Odds ratios (OR) and p-values of these variables
are presented.
Secondary outcome. To identify factors associated with written
TLDs in the study population, a univariate binary logistic
regression analysis was performed including the following
variables: age, gender, marital status, body mass index, CCI,
ECOG Performance Status, malignancy type, metastatic dis-
ease, admission reason, readmission, SOFA score and sepsis.
Subsequently, variables with a p-value <0.2 in the univariate
analysis were evaluated in a multivariate binary logistic regres-
sion analysis. Given the clinical relevance of CCI, type of
malignancy and admission reason, these factors were forced
into the multivariate model. Odds ratios (OR) and p-values of
these variables are presented.
Results
During the study period, 2486 patients were admitted to our ICU,
of which 1046 (42%) unplanned admissions. Of these unplanned
admissions, 125 (12%) patients were diagnosed with an active
malignancy (study population) and 76 (7.3%) patients with CR.
The baseline characteristics of the study population are shown in
Table 1. Themajority of the study populationwas diagnosedwith
a solid tumor (80.8%). The different types of themalignancies are
shown in Appendix A. Written TLDs were made in 30 (24%) of
the patients before ICU admission, themajority weremade by the
medical team for medical reasons (83.3%, Table 1). ICU admis-
sion characteristics are shown inTable 1 aswell.During ICUstay,
awrittenTLDwasmade in another 37patients (29.6%).All of the
written TLDs were made by the medical team, 2 decisions
included explicit patient’s wishes (5.4%).
Patients with a malignancy who received a written TLD
during ICU stay were significantly older than patients without
a malignancy who received a written TLD, but SOFA scores on
Table 1. Characteristics and Outcome Study Population.
Baseline characteristics
Study population
(n ¼ 125)
Agea 66 [59-73]
Male 84 (67.2%)
BMI in kg/m2 b, c 24.0 {21.8-27.1}
Marital status
Married 87 (69.6%)
Without partner 30 (24.0%)
Other 7 (5.6%)
Unknown 1 (0.8%)
Comorbidity
CCI a, d 4 [3-6]
Age-adjusted CCI a, d 6 [4-8]
Patients with a solid malignancy 101 (80.8%)
Patients with a hematological malignancy 21 (16.8%)
Patients with solid and hematological malignancy 1 (0.8%)
Patients with unknown type 2 (1.6%)
Patients with metastatic solid malignancy 33 (26.4%)
TLDf before ICUe admission 30 (24.0%)
Reasons TLDf
Medical reasons 25 (83.3%)
Wish of patient 3 (10%)
Combination 1 and 2 2 (6.7%)
Characteristics ICUe admission
Admission reason
Respiratory failure 29 (23.2%)
Post-operative: emergency operation 20 (16%)
Sepsis 15 (12%)
Post cardiopulmonary resuscitation 5 (4%)
Neurological 10 (8%)
Other 25 (20%)
Combination of reasons 21 (16.8%)
Readmissions 32 (25.6%)
Readmission < 2 days 6 (4.8%)
SOFA value a, g 7 [5 -10]
Mechanically ventilated 83 (66.4%)
Vasopressors 90 (72%)
Renal Replacement Therapy 27 (6.8%)
Sepsis 54 (43.2%)
Outcome
TLDf 37 (29.6%)
DNRf 23 (18.4%)
DNR and other limitations 10 (8.0%)
Only other limitations 4 (3.2%)
Reasons TLDf
Medical reasons 35 (94.6%)
Wish of patient 0 (0%)
Combination of 1 and 2 2 (5.4%)
Medical reasons
Multiple organ failure 14 (37,8%)
Poor neurological prognosis 3 (8.1%)
(Incurable) Malignancy 16 (43.2%)
Progression critical illness despite maximal medical
support
17 (45.9%)
Other 7 (18.9%)
Withdrawal / withholding treatment ICUe 41 (32.8%)
ICUe survival 85 (68%)
(continued)
Table 1. (continued)
Baseline characteristics
Study population
(n ¼ 125)
Hospital survival 70 (56%)
Length of staya, h 3 [1-10]
aData are displayed as median with 25th and 75th percentile
bBMI; Body Mass Index
cA logarithmic transformation was performed, original data was not normally
distributed
dCCI; Carlson Comorbidity Index
eICU; Intensive Care Unit
fDNR; Do-Not-Resuscitate
gSOFA; Sequential Organ Failure Assessment score (SOFA score)
hIn days
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the day of the TLD were not significantly different in patients
with and without a malignancy (Table 2).
The univariate binary logistic regression analysis showed a
higher incidence ofwrittenTLDsduring ICU stay in patientswith
an active malignancy than in patients without a malignancy (OR
1.97; 95% CI 1.29-3.01; Table 3). Having CR was not associated
with a written TLD. Age and severity of illness at ICU admission
(SOFA score) were associated with written TLDs as well.
Age (OR 1.03; 95% CI 1.01 -1.04), SOFA score at ICU
admission (OR 1.11; 95% CI 1.05 -1.18) and an active malig-
nancy (OR 1.75; 95% CI 1.04-2.96) were independently asso-
ciated with written TLDs (multivariate analysis, Table 4).
Secondary outcomes. Of the variables analyzed in the univariate
binary logistic regression analysis of the study population, age
(OR 1.05; 95% CI 1.01 -1.09), SOFA score at admission (OR
1.13; 95%CI 1.03 -1.25) and sepsis (OR 2.57, 95%CI 1.17-5.64)
were associated with a written TLD during ICU stay (Table 5).
After adjustment for the confounders, only age (OR 1.06; 95%CI
1.01 -1.11) remained associated with written TLDs (Table 6).
Appendices B and C show that 30 patients (24%) of the
study population were admitted to the ICU with a written TLD,
and that having an active malignancy is associated indepen-
dently with a written TLD before ICU admission (OR 3.60;
95% CI 2.17-5.97).
Discussion
Treatment limitation decisions on the ICU can be challenging,
especially in patients with a malignancy. Up-to-date literature
regarding TLDs, and factors associated with TLDs, in critically
ill patients with a malignancy admitted unplanned to the ICU is
scarce. The aim of this study was to compare the incidence of
written TLDs between patients with an active malignancy,
patients with CR and patients without a malignancy during ICU
stay. This study shows that having an active malignancy is
independently associated with a higher risk of a written TLD
during ICU stay, while patients with CR were not at risk for a
higher incidence of TLDs.
The outcomes of patients with a malignancy after invasive
life-saving treatments such as CPR and mechanical ventilation
are potentially poor.8,9,32,33 The benefit of these treatments
should be weighed against the possible burden of prolonged
hospitalization and invasive treatment. It may be argued that
our clinicians made TLDs in order to minimize inappropriate
care in case of deterioration, especially when families indicate
that quality of life was important for the patient.
On the other hand, some literature suggested that health care
providers could display implicit “cognitive biases” toward
patients,34,35 leading to a biased evaluation of patients based
on certain characteristics. Biases toward patients with a malig-
nancy among health care providers have been reported in lit-
erature.36 It could be argued that these biases might influence
the perception of inappropriate care, leading to unintended
discrimination of clinicians toward patients with a malignancy
and subsequently more written TLDs in these patients. Litera-
ture suggests the existence of self-fulfilling prophecy (SFP) in
medical decision making, especially in TLD and end-of-life
decisions.37 Although this phenomenon is hypothetical and
cannot be proven with objective studies regarding critically ill
patients with a malignancy, from a psychological point of view,
Table 2. Characteristics Patients With Treatment Limitations
Received During ICU Stay: ICU Population Without Malignancy vs.
Study Population.
General ICUa
population
(n ¼ 146)
Study
population
(n ¼ 37) P-valueb
Agec 64 [54-72] 68 [61-77] 0.02*
Male 103 (62%) 24 (64.9%) 0.75
SOFAd at ICU admission 9 [7-11] 8 [6-11] 0.34
SOFAd at TLD 9 [8-14] 9 [7-12] 0.33
Day TLDe 2 [1-6] 4 [1-8] 0.27
aICU; Intensive Care Unit
bP- value; probability value, a p-value of < 0.05 was considered statistically
significant, marked by an Asterisk *
cData are displayed as median with 25th and 75th percentile
dSOFA; Sequential Organ Failure Assessment score (SOFA score)
Table 3. Univariate Analysis for Factors Associated With TLD During ICU Stay in Patients With and Without a Malignancy.
Variable Patient cases Treatment limitation ORa 95% CIb P-valuec
No malignancy (ref) 825 (78.9%) 145 (17.6%) – – –
Malignancy (active or CRd) 221 (21.1%) 63 (28.5%) 1.87 1.33-2.63 <0.001*
Active malignancy 125 (12.0%) 37 (29.6%) 1.97 1.29-3.01 0.002*
CRd <1 yr 18 (1.7%) 4 (22.2%) 1.34 0.44-4.13 0.61
CRd >1 yr 58 (5.5%) 16 (27.6%) 1.79 0.98-3.27 0.06
Active malignancy þ CRd 16 (1.5%) 5 (31.3%) 2.13 0.73-6.23 0.17
Age – – 1.02 1.01 -1.03 <0.001*
Gender 661 (63.2%) 131 (19.8%) 1.01 0.74 -1.39 0.94
SOFA at ICU admission – – 1.10 1.04 -1.16 0.001*
aOR; Odds ratio
bCI; confidence interval
cP- value; probability value, a p-value of < 0.05 was considered statistically significant, marked by an Asterisk *
dCR; Complete remission
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all clinicians should be aware of SFP. To avoid this pitfall, we
organize a multidisciplinary meeting in our hospital once per
day, including ICU physicians, physicians of the referring spe-
cialism, ICU nurses and if necessary, a clinical ethicist. Deci-
sions concerning treatment limitations are made in this
multidisciplinary meeting, and if possible, based on evidence
in literature in our hospital.
Remarkably, the percentage of written TLD was almost a
threefold higher in our study population than in the population
of a recent study of a specialized Portuguese Cancer institute.38
In our study, the percentage of TLDs in patients without a
malignancy was also higher than the percentage of written
TLDs in ICU patients of large previous studies.39,40 Besides
of differences in case-mix, it is well known that TLDs vary
across countries, regions, hospitals, ICUs, and even among
physicians.38 Religious beliefs, cultural backgrounds and the
ethical climate of the ICU team can all influence such deci-
sions.1 Therefore, the possibility exists that TLDs were actually
made more often by our clinicians in similar patient’s circum-
stances. However, the association between having a malig-
nancy and TLDs was found in previous studies as well.41,42
Our secondary objective was to identify factors indepen-
dently associated with written TLDs in patients with a malig-
nancy. Surprisingly, we found that only age was independently
associated with a TLD, while comorbidity, gender and the
ECOG performance status and severity of illness (SOFA score)
were not associated. The influence of age on treatment-
limitations decisions is consistent with other literature41 while
an association with comorbidity, performance status, gender
and severity of illness was found in other literature.41,42 The
exact reasons for this difference remain unclear. However,
similar to TLDs, ICU admission decisions vary across coun-
tries and regions, with religious beliefs and cultural back-
grounds influencing ICU admissions. A difference in ICU
admission considerations and subsequently a difference in
case-mix may explain this difference with other studies.
Table 5. Univariate Analysis: Factors Associated With TLD During ICU Stay in the Study Population.
Variable Patient cases Treatment limitation ORa 95% CIb P-valuec
Age – – 1.05 1.01 -1.09 0.02*
Gender (male) 84 (67.2%) 24 (28.5%) 0.86 0.38 -1.94 0.72
Marital status-married (ref) 87 (69.6%) 25 (28.2%) – – –
Without partner 30 (24%) 10 (33.3%) 1.24 0.51-3.02 0.64
Other 7 (5.6%) 2 (28.6%) 0.99 0.18-5.45 0.99
BMId – – 1.00 0.92 -1.08 0.93
Comorbidity (CCIe) – – 0.98 0.80 -1.19 0.82
ECOG 0 (ref) 29 (23.2%) 7 (24.1%) – – –
ECOG 1 35 (28%) 8 (22.9%) 0.93 0.29-2.97 0.90
ECOG 2 23 (18.4%) 10 (43.5%) 2.42 0.74-7.9 0.14
ECOG 3 25 (20%) 9 (36%) 1.77 0.54-5.75 0.34
ECOG 4 6 (4.8%) 2 (33.3%) 1.57 0.24-10.49 0.64
Solid (ref) 101 (80.8%) 29 (28.7%) – – –
Hematological 21 (16.8%) 7 (33.3%) 1.24 0.46-3.39 0.67
Metastatic disease 33 (26.4%) 8 (24.2%) 0.91 0.34-2.49 0.86
Admission reason-medical (ref) 92 (73.6%) 27 (29.3%) – – –
Elective surgery 10 (8%) 1 (10%) 0.27 0.03-2.22 0.22
Emergency surgery 20 (16%) 7 (35%) 1.30 0.47-3.60 0.62
Readmission 32 (25.6%) 9 (28.1%) 0.91 0.37-2.21 0.83
SOFA at ICU admission – – 1.13 1.03 -1.25 0.01*
Sepsis 54 (43.2%) 22 (40.7%) 2.57 1.17-5.64 0.02*
aOR; Odds ratio
bCI; confidence interval
cP- value; probability value, a p-value of < 0.05 was considered statistically significant, marked by an Asterisk *
dBMI; Body Mass Index
eCCI; Carlson Comorbidity Index
fECOG; The Eastern Cooperative Oncology Group (ECOG) Performance Status.
gSOFA; Sequential Organ Failure Assessment score (SOFA score)
Table 4. Multivariate Analysis for Factors Independently Associated
with TLD During ICU Stay in Patients with and without a Malignancy.
Covariate ORa 95% CIb P-valuec
Age 1.03 1.01 -1.04 0.001*
Active malignancy 1.75 1.04-2.96 0.04*
CRd>1yr 1.48 0.72-3.05 0.29
Active malignancy þ CRd 1.40 0.41-4.77 0.59
SOFAe at ICU admission 1.11 1.05 -1.18 0.001*
aOR; Odds ratio
bCI; confidence interval
cP- value; probability value, a p-value of < 0.05 was considered statistically
significant, marked by an Asterisk *
dCR; Complete remission
eSOFA score; Sequential Organ Failure Assessment score (SOFA score)
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In our study population, 75% did not have a treatment lim-
itation before ICU admission, while the national guideline
regarding critically ill patients with a malignancy states that
the decision whether treatment limitations are appropriate
should be made prior to an ICU admission. The absence of
treatment limitations is acceptable in case of a good prognosis.
Failure to discuss a treatment limitation due to difficulty with
prognostication or due to inadequate or poor communication is
reprehensible. This might lead to an inappropriate ICU admis-
sion and subsequently to a higher incidence of TLDs in patients
with a malignancy during ICU admission. Early and proper
education about impact and outcome is important to improve
prognostication and communication of clinicians.43-46
All the TLD in our study population were made by the
medical team in a multidisciplinary meeting, which is compa-
rable to other literature.47 In Europe, TLDs are often made by
the medical team. North American clinicians commonly apply
standards or formal procedures and TLDs are more often made
with family involvement due to the insurance system and the
increase in litigation.47 However, caution regarding family
involvement is recommended due to the following reasons:
first, the knowledge of CPR in the general population is poor,
mostly due to television medical dramas with poor representa-
tion of CPR and its outcome;48 second, family is often not able
to adequately predict patient’s wishes49; last, a TLD made by
family could cause a significant burden on the family and may
result in anxiety or depression.50 Therefore a more paternalistic
approach could be justified if the relevant factors for adequate
decision making can be identified.
Limitations and Strengths
First, the most important limitation of this study is the hetero-
geneous study population of this study, with different types of
malignancies, differences in extensiveness of the malignancy
and differences in cancer treatment before ICU admission.
However, in our univariate analysis, no evidence of difference
in TLD incidence was found between patients with a solid
tumor and patients with a hematological malignancy and
between non-metastatic disease and metastatic disease. More-
over, unintended discrimination by clinicians will be associated
with the word cancer in general, not with a specific type of
malignancy.
Second, physicians made a well-considered decision
whether to admit the patient to the ICU, this could
have influenced the incidence of TLDs before and during ICU.
Third, data were collected from a single institution, which
can restrict generalizability.
Last, this was a retrospective study, and all the limitations of
a retrospective review could be inherent in our study.
Conclusions
This study shows that the presence of an underlying malig-
nancy is independently associated with written TLDs during
ICU stay. Patients with CR are not at risk of more written
TLDs. TLDs are mostly made by the medical team. This is
justifiable when made in order to minimize inappropriate care
in case of deterioration. However, all clinicians should be
aware of unintended discrimination toward patients with a
malignancy. Therefore, TLDs should be made in a multidis-
ciplinary meeting.
Table 6.Multivariate Analysis: Factors Independently Associated with
TLD During ICU Stay in the Study Population.
Covariate ORa 95% CIb P-valuec
Age 1.06 1.01 -1.11 0.03*
Hematological malignancy 1.25 0.31-5.05 0.75
Admission reason-medical (ref)
Elective surgery 0.61 0.06-6.37 0.68
Emergency surgery 1.78 0.46-6.88 0.40
SOFA at ICU admissione 1.14 0.98 -1.32 0.09
Sepsis 1.55 0.53-4.50 0.43
CCI 0.84 0.65 -1.09 0.20
ECOG 1 1.19 0.26-5.41 0.83
ECOG 2 4.19 0.89-19.75 0.07
ECOG 3 1.75 0.41-7.51 0.45
ECOG 4 1.48 0.17-12.92 0.72
aOR; Odds ratio
bCI; confidence interval
cP- value; probability value, a p-value of < 0.05 was considered statistically
significant, marked by an Asterisk *
dICU; Intensive Care Unit
eSOFA; Sequential Organ Failure Assessment score (SOFA score)
Appendix A. Numbers and Percentage Malignancy Types.
Total study population
(n ¼ 125)
Type Solid malignancy
Bladder carcinoma 4 (3.2%)
Cholangiocarcinoma 10 (8%)
Colorectal carcinoma 17 (13.6%)
Gastric carcinoma 3 (2.4%)
Hepatocellular carcinoma 3 (2.4%)
Larynx carcinoma 1 (0.8%)
Lung carcinoma 12 (9.6%)
Malignancy of central nerve system 4 (3.2%)
Melanoma 3 (2.4%)
Mesothelioma 3 (2.4%)
Neuroendocrine tumor 4 (3.2%)
Esophagus carcinoma 14 (11.2%)
Other 20 (16%)
Prostate carcinoma 5 (4%)
Sarcoma 1 (0.8%)
Type hematological malignancy
Acute lymphoid leukemia 2 (1.6%)
Acute myeloid leukemia 6 (4.8%)
Non-Hodgkin Lymphoma 3 (2.4%)
Other 11 (8.8%)
The different types of the malignancies, note: some patients have more than 1
malignancy
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